Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Optical Scanner Advances Cervical Cancer Screening

By HospiMedica International staff writers
Posted on 02 Jun 2016
A new technology optimizes the cervical cancer (CC) screening process into a single, three-minute painless optical scan.

The Biop device is a probe inserted into the vaginal canal that optically identifies and classifies epithelium based cancers and pre-cancerous lesions. More...
Once inserted, the probe scans the entire cervix; images and optical signatures are captured by integrated sensors and analyzed by a proprietary algorithm. The result is two images placed side-by-side on the physician's screen; a high-resolution photograph of the patient's cervix, and a thermal map indicating a precise classification and location of any diseased lesions.

A panoramic photograph of the cervix from outside of the vaginal canal can also be taken, similar to that of a traditional colposcope. This can provide the practitioner with complete information of any other vaginal lesions, including any not on the cervix itself. The data is automatically uploaded to the electronic health record (EHR), and is also stored in a cloud-based proprietary database for follow up. Follow up exams are automatically compared to earlier exams, with any changes automatically noted.

Biop can also be used in an ambulatory setting, allowing for mobile cervical screening, similar to mobile blood units and mobile breast cancer screening programs, This can be useful in areas where socialized medicine has created a long wait between an abnormal Pap and an appointment for a colposcopy, providing a better prognosis for women who have CC. The Biop device is under development by Biop Medical (Ramat Gan, Israel).

“The Biop device is perfect for any setting, especially for doctors and nurses in rural areas who don’t have — and can’t afford — the fancy equipment usually needed to test for cervical cancer,” said Ilan Landesman, founder and CEO of Biop Medical. “It’s a big-data solution that can replace traditional methods of examining for cervical cancer.”

In current clinical practice, the diagnosis of CC is mainly through the cervical screening followed by a necessary biopsy, but this method is labor consuming and expensive, and can only detect superficial lesions around the external cervical orifice. In contrast, PAI is sensitive to the abnormal angiogenesis deep in the biological tissue, and may be capable for the intact scanning both around the external orifice and in cervical canal.

Related Links:
Biop Medical


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.